Cardiovascular effects of common analgesics

Medical Journal of Malaysia

Volumn 68, Issue 2, 2013, Pages 189-194

  Ong, H T ^a   Ong, L M ^b   Tan, T E ^c   Chean, K Y ^d  

^a HT Ong Heart Clinic   (Malaysia)

^b Penang Hospital   (Malaysia)

^c Penang Adventist Hospital   (Malaysia)

^d PENANG MEDICAL COLLEGE   (Malaysia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; CELECOXIB; CORTICOSTEROID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DICLOFENAC; ETODOLAC; ETORICOXIB; IBUPROFEN; INDOMETACIN; MELOXICAM; MORPHINE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PIROXICAM; PLACEBO; ROFECOXIB; VALDECOXIB; CYCLOOXYGENASE 2 INHIBITOR;

ARTICLE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG WITHDRAWAL; FLUID RETENTION; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HUMAN; HYPERTENSION; META ANALYSIS (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; UNSPECIFIED SIDE EFFECT; CARDIOVASCULAR DISEASE; PAIN; RISK FACTOR;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARDIOVASCULAR DISEASES; CYCLOOXYGENASE 2 INHIBITORS; HUMANS; PAIN; RISK FACTORS;

EID: 84876909444     PISSN: 03005283     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. NL Rhodus. Prostaglandins: promulgators of pain. Anesth Prog 1979; 26: 73-75.
2. Ricciot Ti E, FitzGerald GA. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol 2011; 31: 986-1000.
3. Kelton JG, Blajchman MA. Prostaglandin I2 (prostacyclin). Can Med Assoc J 1980; 122: 175-179.
4. Vane JR, Botting RM. New insights into the mode of action of anti-inflammatory drugs. Inflamm Res 1995; 44: 1-10.
5. Fitzgerald GA. Coxibs and cardiovascular disease. N Engl J Med 2004; 351: 1709-1711.
6. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. New Engl J Med 1999; 340: 1888-1899.
7. Langman MJ, Weil J, Wainwright P, et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343: 1075-1078.
8. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284: 1247-1255.
9. Bombardier C, Laine L, Reicin A, et al. For the VIGOR Study Group. Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis. N Engl J Med 2000; 343: 1520-1528.
10. Hunt RH, Harper S, Watson DJ, et al. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events. Am J Gastroenterol. 2003; 98: 1725-1733.
11. Watson DJ, Harper SE, Zhao PL, Quan H, Bolognese JA, Simon TJ. Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis. Arch Intern Med 2000; 160: 2998-3003.
12. Watson DJ, Yu Q, Bolognese JA, Reicin AS, Simon TJ. The upper gastrointestinal safety of rofecoxib vs. NSAIDs: an updated combined analysis. Curr Med Res Opin 2004; 20: 1539-1548.
13. Marnett LJ. The COXIB experience: a look in the rearview mirror. Annu Rev Pharmacol Toxicol 2009; 49: 265-290.
14. Maxwell SR, Webb DJ. COX-2 selective inhibitors--important lessons learned. Lancet 2005; 449-451.
15. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001; 286: 954-959.
16. White WB, Strand V, Roberts R, Whelton A. Effects of the clyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal anti-inflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis. Am J Ther 2004; 11: 244-250.
17. Bresalier RS, Sandler RS, Quan H, et al. Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352: 1092-1102.
18. Solomon SD, McMurray JJ, Pfeffer MA, et al. Adenoma Prevention with Celecoxib (APC) Study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352: 1071-1080.
19. US Food and Drug Administration. Questions and Answers FDA Regulatory Actions for the COX-2 Selective and Non-Selective Non-Steroidal Anti-inflammatory drugs (NSAIDs). April 2005. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformation forPatientsandProviders/ucm106148.htm.
20. Graham DJ. COX-2 inhibitors, other NSAIDs and cardiovascular risk. The seduction of common sense. JAMA 2006; 296: 1653-1656.
21. Ricciotti E, FitzGerald GA. Prostaglandins and inflammation disease. Arterioscler Thromb Vasc Biol 2011; 31: 986-1000.
22. FitzGerald GA. Coxibs and cardiovascular disease. N Engl J Med 2004; 351: 1709-1711.
23. McGettigan P, Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med 2011; 8(9): e1001098.
24. Johnsen SP, Larsson H, Tarone RE, et al. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. Arch Intern Med 2005; 165: 978-984.
25. Gislason GH, Rasmussen JN, Abidstrom SZ, et al. Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. Arch Intern Med. 2009 Jan 26; 169(2): 141-149.
26. Cannon CP, Curtis SP, FitzGerald GA, et al. MEDAL Steering Committee. Cardiovascular outcomes with etoricoxib and diclofenan in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparision. Lancet. 2006 Nov 18; 368(9549): 1771-1781.
27. Solomon DH, Glynn RJ, Rothman KJ, et al. Subgroup analyses to determine cardiovascular risk associated with nonsteroidal antiinflammatory drugs and coxibs in specific patient groups. Arthritis Rheum 2008; 59: 1097-1104
28. Strand V. Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin? Lancet 2007; 370: 2138-2151.
29. Hall M, Griffiths R, Appadu B. Is morphine indicated in acute pulmonary oedema? Emerg Med J 2005;22: 391.
30. Graham GG, Graham RI, Day RO. Comparative analgesia, cardiovascular and renal effects of celecoxib, rofecoxib and acetaminophen (paracetamol). Curr Pharm Des 2002; 8: 1063-1075.
31. Hinz B, Brune K. Paracetamol and cyclooxygenase inhibition: is there a cause for concern? Ann Rheum Dis 2012; 71: 20-25.
32. Forman JP, Stampfer MJ, Curhan GC. Non-narcotic analgesic dose and risk of incident hypertension in US women. Hypertension 2005; 46: 500-507.
33. Sholter DE, Armstrong PW. Adverse effects of corticosteroids on the cardiovascular system. Can J Cardiol 2000; 16: 505-511.
34. Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med 2004; 141: 764-770.
35. Stanbury RM, Graham EM. Systemic corticosteroid therapy-side effects and their management. Br J Ophthalmol 1998; 82: 704-708.
36. Parekh AK, Galloway JM, Hong Y, Wright JS. Aspirin in the secondary prevention of cardiovascular disease. N Engl J Med 2013; 368: 204-205.
37. Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 2006; 295: 306-313.
38. De Berardis G, Lucisano G, D'Ettorre A, et al. Association of aspirin use with major bleeding in patients with and without diabetes. JAMA 2012; 307: 2286-2294.
39. Massie BM. Aspirin use in chronic heart failure. What should we recommend to the practitioner? J Am Coll Cardiol 2005; 46: 963-966.
40. Massie BM, Collins JF, Ammon SE, et al. WATCH Trial Investigators. Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. Circulation 2009; 119: 1616-1624.
41. Segal R, Lubart E, Leibovitz A, Iaina A, Caspi D. Renal effects of low dose aspirin in elderly patients. Isr Med Assoc J 2006; 8: 679-682.
42. Henry D, Lim LL, García Rodríguez LA, et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 1996; 312: 1563-1566.
43. Olsen AMS, Fosbol EL, Lindhardsen J, et al. Duration of treatment with non-steroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. Circulation 2011; 123: 2226-2235.